Inarigivir soproxil clinical trials
Also written SB 9200.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How each study uses inarigivir soproxil is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
F-star Therapeutics, Inc. (4) · Syneos Health (1) · Gilead Sciences (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses inarigivir soproxil is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)TerminatedPhase 2Gilead SciencesNCT03434353Written as Inarigivir Soproxil
- Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC InhibitorTerminatedPhase 2F-star Therapeutics, Inc.NCT04023721Written as Inarigivir soproxil
- Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B VirusTerminatedPhase 2F-star Therapeutics, Inc.NCT04059198Written as Inarigivir soproxil
- Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B PatientsTerminatedPhase 2F-star Therapeutics, Inc.NCT03932513Written as inarigivir soproxil
- A Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic HBVCompletedPhase 2F-star Therapeutics, Inc.NCT02751996Written as SB 9200
- A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C InfectionCompletedPhase 1Syneos HealthNCT01803308Written as SB9200
Codes
What other systems call inarigivir soproxil · ClinicalTrials.gg INT014597
- UNII (FDA) 365052M0DKINARIGIVIR SOPROXILOne source FDA
- NCI Thesaurus C166642Inarigivir SoproxilOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 365052M0DK | INARIGIVIR SOPROXIL | One source FDA |
| NCI Thesaurus | C166642 | Inarigivir Soproxil | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.